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ABSTRACT
Background Lung cancer screening using low-dose CT
(LDCT) was shown to reduce lung cancer mortality by
20% in the National Lung Screening Trial.
Methods The pilot UK Lung Cancer Screening (UKLS)
is a randomised controlled trial of LDCT screening for
lung cancer versus usual care. A population-based
questionnaire was used to identify high-risk individuals.
CT screen-detected nodules were managed by a pre-
specified protocol. Cost effectiveness was modelled with
reference to the National Lung Cancer Screening Trial
mortality reduction.
Results 247 354 individuals aged 50–75 years were
approached; 30.7% expressed an interest, 8729
(11.5%) were eligible and 4055 were randomised, 2028
into the CT arm (1994 underwent a CT). Forty-two
participants (2.1%) had confirmed lung cancer, 34
(1.7%) at baseline and 8 (0.4%) at the 12-month scan.
28/42 (66.7%) had stage I disease, 36/42 (85.7%) had
stage I or II disease. 35/42 (83.3%) had surgical
resection. 536 subjects had nodules greater than
50 mm3 or 5 mm diameter and 41/536 were found to
have lung cancer. One further cancer was detected by
follow-up of nodules between 15 and 50 mm3 at
12 months. The baseline estimate for the incremental
cost-effectiveness ratio of once-only CT screening, under
the UKLS protocol, was £8466 per quality adjusted life
year gained (CI £5542 to £12 569).
Conclusions The UKLS pilot trial demonstrated that it
is possible to detect lung cancer at an early stage and
deliver potentially curative treatment in over 80% of
cases. Health economic analysis suggests that the
intervention would be cost effective—this needs to be
confirmed using data on observed lung cancer mortality
reduction.
Trial registration ISRCTN 78513845.
INTRODUCTION
Almost three-quarters of people with lung cancer
present with advanced stage disease, when treatment
has little effect on survival. In 2010 the US-based
National Lung Cancer Screening Trial (NLST) was
stopped 1 year early because a 20% relative
reduction in lung cancer mortality had been
achieved by low-dose CT compared with chest x-ray
after three annual screens and 6 years of follow-up.1
Subsequent publications have identified a number of
areas where improvements can be made.2 Six recom-
mendations were made in the International
Association for the Study of Lung Cancer (IASLC)
CT screening workshop report,3 with a focus on
future implementation. These were:
1. Optimisation of identification of high-risk
individuals.
2. Development of radiological guidelines.
3. Development of guidelines for the clinical
workup of indeterminate nodules.
4. Development of guidelines for pathology
reporting.
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Key messages
What is the key question?
▸ Is lung cancer CT screening a viable option in
the UK and is it cost effective?
What is the bottom line?
▸ A single low-radiation dose CT screen in people
at high risk of lung cancer as selected by a
validated risk prediction model led to a 2.1%
detection rate with 86% stage I and II and an
83% resection rate.
Why read on?
▸ The UK Lung Cancer Screening pilot trial is the
first to use a true population approach to
selection with a validated individual risk
assessment and shows that, with volumetric
nodule measurement and pre-specified clinical
pathways, it is possible to detect lung cancer at
an early stage and deliver potentially curative
treatment in over 80% of cases: health
economic analysis suggests that the
intervention would be cost effective, but this
needs to be confirmed using data on observed
lung cancer mortality reduction.
Field JK, et al. Thorax 2016;71:161–170. doi:10.1136/thoraxjnl-2015-207140 161
Lung cancer
5. Definition of criteria for surgical and therapeutic interven-
tions of suspicious nodules identified through lung cancer
CT screening programmes.
6. Development of recommendations for the integration of
smoking cessation practices into future national lung cancer
CT screening programmes.
Resolution of these issues is important to ensure that future
national lung cancer screening programmes target a population
at high enough risk of developing lung cancer while minimising
the potential for harm, in a cost-effective way.4
The aims of the UK Lung Cancer Screening (UKLS) pilot trial
were to demonstrate the effectiveness of risk prediction modelling
for the selection of high-risk participants; to evaluate the use of
volumetric analysis in the management of CT-detected nodules
linked with pragmatic follow-up strategies; and to determine cost
effectiveness based on modelling of the pilot UKLS approach.
METHODS
The UKLS trial received approval from the National
Information Governance Board. Ethical approval for the study
was given by Liverpool Central Research Ethics Committee in
December 2010 (reference number 10/H1005/74). The trial
was registered with the International Standard Randomised
Controlled Trial Register under the reference 78513845.
The UKLS is a randomised controlled trial of low-dose CT
(LDCT) screening versus standard care for the early detection
of lung cancer in high-risk individuals. The study follows the
Wald Single Screen Design, as described previously.5
Sample size
We designed the pilot to give a precise estimate of the propor-
tion of subjects complying with screening. A study size of 4000
and therefore 2000 in the intervention arm would enable us to
estimate 80% compliance with a 95% CI not exceeding ±2%.
UKLS trial design
The Wald single-screen design was adopted because it is the
most economical approach in terms of the number of CT screen-
ing examinations needed for a fully powered trial5 (as it was ori-
ginally planned that 32 000 individuals were to be randomised
in the main UKLS trial). It will also provide early data on rates
of cancers in the years following a screen, to inform the most
appropriate ‘interval’ for subsequent screens. It will produce
mortality results in a similar timeframe to the other major inter-
national multicentre screening trials, and allow us to synchronise
our data. In addition, the single screen design does not have the
problem of long-term compliance.
Identification of Individuals with a high risk of developing
lung cancer
The eligibility criteria in the current two largest randomised
controlled trials (NLST and NELSON) were based on smoking
history and age,1 6 However, risk of lung cancer is also influ-
enced by other factors that can be used to refine risk prediction
and improve selection.
The Liverpool Lung Project (LLP) risk model was based on a
case–control study.7 It is a multivariable conditional logistic
regression model based on factors significantly associated with
lung cancer (smoking duration, prior diagnosis of pneumonia,
occupational exposure to asbestos, prior diagnosis of malignant
tumour and early onset (<60 years) family history of lung
cancer).7 The multivariable model was combined with
age-standardised incidence data to estimate the absolute risk of
developing lung cancer. The discrimination of the LLP was
evaluated and demonstrated its predicted benefit for stratifying
patients for CT screening by using data from three independent
studies from Europe and North America.8
The LLPv2 model includes all respiratory disease (COPD,
emphysema, bronchitis, pneumonia and TB9) and all smokers
(cigarettes, pipe and cigars) to select subjects with ≥5% risk of
developing lung cancer in the following 5 years.10 The risk pre-
diction model is available on http://www.MylungRisk.org.
Inclusion and exclusion criteria
Inclusion criteria
A 5-year lung cancer risk of ≥5%, based on the LLPv2 risk pre-
diction model,7 8 10 men and women aged between 50 and
75 years old, ability to provide fully informed written consent.
Exclusion criteria
Inability to give consent, comorbidity which would unequivo-
cally contraindicate either screening or treatment if lung cancer
were detected, thoracic CT performed within 1 year preceding
the invitation to be screened, inability to lie flat.
Recruitment
We identified 249 988 individuals from population Primary
Care Trust records, aged 50–75 years, residing in specific health-
care areas (Liverpool, Knowsley, Sefton; Cambridgeshire,
Peterborough, and Bedfordshire). Questionnaires were sent to
247 354 individuals to identify those at high risk (≥5% over
5 years) of developing lung cancer. The first UKLS approach
questionnaire is available on the UKLS website (http://www.
UKLS.org) and was distributed by Radar, the third party
data management company (http://www.marketingradar.com).
A second questionnaire was sent to individuals considered to be
at high risk, inviting them to participate in the UKLS trial
(http://www.UKLS.org). Recruited subjects were randomly allo-
cated by simple computer pseudo-random number generation to
either the intervention (LDCT) or control arms in a 1:1 ratio.
Figure 1 illustrates the trial recruitment process.
CT
CT scans were performed on Siemens 128-slice scanners
(Siemens, Erlangen, Germany) at Papworth Hospital,
Cambridgeshire and Liverpool Heart and Chest Hospital
(LHCH). In the initial phase of the trial, from November 2011
to December 2011, a Philips Brilliance 64 slice scanner (Philips,
Best, The Netherlands) was used at LHCH, using the same
acquisition parameters.
Thoracic CT images were obtained from lung apices to bases,
during suspended inspiration, in a single breath hold and
without the administration of intravenous contrast. Images were
reconstructed at 1 mm thickness at 0.7 mm increments, using a
moderate spatial frequency kernel reconstruction algorithm.
Acquisition parameters (kVp and mAs) varied according to body
habitus to achieve a CT dose index below 4 milliGray.
Reading methods
To optimise nodule detection, all baseline CTs were read by two
experienced thoracic radiologists, one at the local trial centres
(LHCH or Papworth Hospital) and one at a central site (Royal
Brompton Hospital (RBH)). All discrepancies were reviewed by
a third thoracic radiologist at RBH, who was the final arbiter.
Once consensus had been reached, a letter was sent to the par-
ticipant and their GP giving the results of the CT.
Readers were required to identify and record all lung nodules
greater than 15 mm3 or 3 mm in maximum diameter (when
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volumetry was not possible) as per the UKLS nodule manage-
ment protocol (figure 2). CTs were read using nodule volumetry
software (Siemens Syngo LungCare). Maximum intensity projec-
tions (MIPs) were used to aid detection.
Nodule management
Classification of CT findings was based on the UKLS radiology
protocol, utilising nodule diameter and volume, on the Siemens
LungCARE software platform. Nodule management is shown in
figure 2; a summary is given below:
▸ No nodules or category 1 (benign) nodules: no further
action required.
▸ Category 2 (small, probably benign) nodules: follow-up CT
scan at 12 months.
▸ Category 3 (larger, potentially malignant) nodules: follow-up
CT scan at 3 months and 12 months.
Figure 1 UK Lung Cancer Screening (UKLS) trial recruitment and implementation process. LDCT, low-dose CT scan; MDT, multidisciplinary team.
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▸ Category 4 (higher chance of malignancy) nodules: immedi-
ate referral to multidisciplinary team (MDT).
Nodules greater than 500 mm3 or 10 mm maximum diameter
at baseline (category 4) or nodules that demonstrated growth on
follow-up CT (as defined by a volume doubling time
<400 days) were referred to the local MDT for further
assessment.
The nodule management protocol has many similarities to
that used by the NELSON trial, except that a cutoff volume of
15 mm3 was specified to minimise the risk of missing small lung
cancers within the single screen design.
Assessment of harms
All procedures performed by the local MDTs were recorded
along with any complications. Detailed psychological assess-
ments were made at intervals during the study; these are the
subject of separate planned publications.
The proposed outcomes of the pilot UKLS Trial
▸ Population-based recruitment based on risk stratification.
▸ Trial management through a web-based database.
▸ Define optimal characteristics of CT readers (radiologists vs
radiographers).
▸ Characterisation of CT-detected nodules utilising volumetric
analysis.
▸ Prevalence of lung cancer at baseline.
▸ Socio-demographic factors affecting participation.
▸ Psychosocial measures (cancer distress, anxiety, depression,
decision satisfaction).
▸ Cost-effectiveness modelling.
Statistical treatment of data for this paper was restricted to
description of numbers and percentages responding who were
eligible, recruited and screened, with outcomes of the screening.
Cost-effectiveness modelling based on UKLS pilot data
A full UKLS trial was planned to follow the pilot: this would have
randomised an additional 28 000 subjects but was not funded.
The pilot UKLS trial was not powered to evaluate mortality reduc-
tion and this short follow-up period precluded adopting the con-
ventional approach to trial evaluation, namely, the measurement
of long-term costs and outcomes in the test and control arms, and
the comparison thereof. Thus, the observational element of the
economic evaluation was restricted to those events and findings
that occurred within the active trial period. The detailed modelling
methodology for calculating the UKLS cost effectiveness is
described in the online supplementary section.
RESULTS
Recruitment
From the 247 354 people sent questionnaires, 148 608 (60.1%)
were non-responders (no questionnaire returned), 22 788
(9.2%) were negative responders (non-participation
Figure 2 UK Lung Cancer Screening (UKLS) nodule care pathway management protocol. LDCT, low-dose CT scan; MDT, multidisciplinary team;
VDT, volume doubling time.
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questionnaire returned) and 75 958 (30.7%) were positive
responders (questionnaire returned; willing to participate). Of
the positive responders, 8729 (11.5%) were classified by the
LLPv2 as high risk, with a risk of ≥5% of developing lung
cancer over the next 5 years (mean LLPv2 risk score=8.8%
versus 1.0% for the low risk group). A total of 5967/8729
(68.4%) high-risk responders returned the second questionnaire
and agreed to participate; 1291 of these were subsequently
excluded for the following reasons: they did not meet the inclu-
sion criteria; they had not completed the eligibility question-
naire correctly; they replied after maximum trial recruitment
numbers had been reached; or they were unable to give fully
informed consent. Five hundred and eighty-two individuals
either changed their mind or failed to attend clinic, and a
further 33 attended the recruitment clinic but declined to
consent. No stratification criteria were used. In total, 4061 indi-
viduals (5.3% of all positive responders, and 46.5% of all high-
risk positive responders) consented and were recruited into the
UKLS.
Figure 3 shows the participant flow from invitation through
to randomisation. Figure 4 provides the percentage of UKLS
positive responders (n=75 958) with an LLP risk of ≥5%, by
individual age; there was a steady increase with age in the per-
centage of people at high risk, with very low numbers at age
50–54.
A total of 73 934 (97.3%) of the positive responders gave
information about their smoking habits: 43.4% were never
smokers, 14.7% current smokers and 39.3% ex-smokers.
A total of 22 024 (96.6%) of the 22 788 negative responders
gave information on smoking habit: 51.3% were never smokers,
9.1% current smokers and 36.2% ex-smokers.
CT screened participants
A total of 1994 participants underwent CT by July 2014; 42
participants (2.1%) were diagnosed with lung cancer, 34 (1.7%)
at baseline and 8 (0.4%) were diagnosed within 12 months with
follow-up CT. Characteristics of individuals in both arms of the
trial were very similar (table 1). The date of censoring was 30
September 2014.
Nodules and management
There were 1015 (50.9%) subjects with category 2–4 nodules;
479/1994 (24%) subjects with category 2 nodules underwent a
12-month repeat scan. Seven of 479 (1.5%) were referred to the
MDT, of whom 1/479 (0.2%) was diagnosed with lung cancer
(table 2).
Four hundred and seventy-two subjects (23.7%) had category
3 nodules and underwent a 3-month interval CT. Forty-three of
the participants (9.1%) were referred to the MDT. A total of
nine (1.9%) lung cancers were diagnosed; two at month three
and seven at the 12-month repeat scan.
Of 64 participants with category 4 nodules who were referred
directly to the MDT, 32 (50%) had lung cancer (table 3).
Diagnostic workup and false positives
In the UKLS, we defined false positives as those requiring
further diagnostic investigation more immediately than a repeat
annual screen, but who subsequently did not have lung cancer.
Figure 3 Participant flow from initial contact to CT screening.
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This is because future screening programmes are likely to
include annual or biennial screens. Overall, 951/1994 (47.7%)
of subjects underwent at least one further CT after the initial
screen.
For complete clarity, the proportion of false positive tests is
now provided in two ways, which allows an appreciation, in a
patient-centred approach, of the variable impact on the subject
in a trial or the patient in a programme. A ‘false positive’ that
mandates referral to the lung cancer MDTwill usually be asso-
ciated with significant psychological distress and additional
more or less invasive investigations with, in some cases, defini-
tive treatment. An individual with a false positive test so defined
is thus more likely to suffer harm than one defined in a different
way; that is, those subjects who are recalled solely for further
CT imaging to clarify the nature of a nodule. The latter is best
termed ‘interval imaging rate’ and may, in screening pro-
grammes, merely mean continuing in the programme rather
than referral to the MDT. For this reason, all category 3 lesions
without cancer are reported separately as false positives warrant-
ing interval imaging. Category 2 findings are not classified as
false positives warranting recall as the cancer rate was found to
be so low in this study that interval imaging would not be
recommended.
Thus on examining the number of UKLS participants referred
to the MDT clinic, the false-positive rate is 3.6% (114-42/
1994=3.6); whilst the interval imaging rate is 23.2% (472-9/
1994).
In total, 114/1994 (5.7%) participants were referred to the
MDT, of whom 42 (2.1% of all screened) had lung cancer.
Pathology
Of the 42 screen-detected cancers, there were 25 adenocarcin-
omas, 12 squamous cell carcinomas, 3 small cell carcinomas, 1
typical carcinoid, and 1 bronchogenic carcinoma. Twenty-eight
of 42 (66.7%) lung cancers were detected at stage I and 8/42
(19%) at stage II (table 3). In total, 36/42 (85.7%) were stage I
or II.
Treatment
Thirty-five of 42 subjects (83%) had surgery as their primary
treatment, with eight having adjuvant chemotherapy.
Thirty-three of the 36 patients with stage I and II lung cancer
had surgery (91.6%) and a further two had radical radiotherapy
(total 97%). In the seven patients who did not undergo resec-
tion, lung cancer diagnoses were made radiologically in one
individual and via tissue biopsy in six patients. Four patients
Figure 4 Percentage of UK Lung
Cancer Screening (UKLS) positive
responders (n=75 958) with a
Liverpool Lung Project (LLPv2) risk of
>5%, by individual age.
Table 1 Demographic, risk and medical characteristics of n=4055
individuals randomised to the UK Lung Cancer Screening (UKLS)
intervention (CT screen) and control (non-screen) trial arms
Total n=4055
Screen arm
(n=2028)
Control arm
(n=2027)
Male:female ratio 1529:499 (3.06:1) 1507:520 (2.90:1)
North:south ratio 1023:1005 (1.02:1) 1023:1004 (1.02:1)
Mean (SD) age, years 67.1 (4.1) 66.9 (4.1)
Median age, years 67 67
Median IMD rank* 17 374 17 704
Mean (SD) LLPv2 score 8.87 (5.12) 8.83 (4.71)
Median LLPv2 score 7.11 7.35
Never smokers 2 (0.1) 0 (0%)
Current smokers 777 (38.3%) 791 (39.0%)
Ex-smokers 1249 (61.6%) 1236 (61.0%)
Smoking duration 10–19 years† 117 (5.8%) 116 (5.7%)
Smoking duration 20+ years† 1895 (93.4%) 1907 (94.1%)
Smoking duration unknown† 14 (0.7%) 4 (0.2%)
% Asbestos exposed 763 (37.6%) 763 (37.6%)
% with history of respiratory
disease‡
1056 (52.1%) 1023 (50.5%)
% with history of blood cancer§ 26 (1.28%) 31 (1.53%)
% with history of solid tumour¶ 378 (18.6%) 396 (19.5%)
Total % with family history of lung
cancer
498 (24.6%) 554 (27.3%)
% with family history of lung
cancer <60 years
215 (10.6%) 215 (10.6%)
% with family history of lung
cancer >60 years
283 (14.0%) 339 (16.7%)
Family history of other cancer (not
lung)**
1026 (50.6%) 1019 (50.3%)
*Index of Multiple Deprivation (IMD) rank (https://www.gov.uk/government/
collections/english-indices-of-deprivation).
†All smoking duration figures refer to current and ex-smokers combined.
‡Asthma, bronchitis, TB, pneumonia, COPD or emphysema.
§Leukaemia or lymphoma, including Hodgkin’s.
¶Cancers of brain, head and neck, oesophagus, breast, colon or ‘other’.
**Cancers of brain, head and neck, oesophagus, breast, colon or ‘other’.
LLP, Liverpool Lung Project.
166 Field JK, et al. Thorax 2016;71:161–170. doi:10.1136/thoraxjnl-2015-207140
Lung cancer
Table 2 Numbers of UKLS individuals in each Nodule category; MDT referral and the number of confirmed lung cancers.
Nodule category (management) Cat 1 (discharged)
Cat 2 (repeat scan
at 12 months)
Cat 3 (repeat scan
at 3 months then 12 months)
Cat 4 (immediate MDT
referral) Total
Number in category 979 479 472 64 1994
Number referred to MDT 0 (N/A) 7 43 64 114
Number of confirmed lung cancers 0 (N/A) 1 9 32 42
MDT, multidisciplinary team.
Table 3 Lung cancer diagnosed in pilot UK Lung Cancer Screening (UKLS)
UKLS case No Baseline nodule category* Sex Age TNM Final Stage Diagnosis Treatment
1 4 M 59 pT1a pN0 IA Adenocarcinoma Surgery
2 4 M 66 pT1a pN0 IA Adenocarcinoma Surgery
3 4 M 66 pT1a pN0 IA Adenocarcinoma Surgery
4 4 M 55 pT1b pN0 IA Adenocarcinoma Surgery
5 4 M 63 pT1a pN0 IA Adenocarcinoma Surgery
6 4 F 64 pT1a pN0 IA Adenocarcinoma Surgery
7 4 M 67 pT1b pN0 IA Small cell carcinoma Surgery/chemotherapy
8 4 M 62 pT1a pN0 IA Squamous cell carcinoma Surgery
9 4 M 68 pT1b pN0 IA Squamous cell carcinoma Surgery
10 4 M 67 pT1a pN0 IA Squamous cell carcinoma Surgery
11 4 M 73 pT1b pN0 IA Squamous cell carcinoma Surgery
12 4 M 71 pT1a pN0 IA Adenocarcinoma Surgery
13 4 M 72 cT1b cN0 cM0 IA Adenocarcinoma Radiotherapy
14 4 M 64 pT1b pN0 IA Adenocarcinoma Surgery
15 4 M 68 pT1a pN0 IA Adenocarcinoma Surgery
16 4 M 74 cT1a cN0 cM0 IA Bronchogenic carcinoma Palliative
17 4 M 69 pT1a pN0 IA Squamous cell carcinoma Surgery
18 4 M 70 pT2a pN0 IB Adenocarcinoma Surgery
19 4 M 67 pT2a pN0 IB Adenocarcinoma Surgery
20 4 M 68 pT2a pN1 IIA Squamous cell carcinoma Surgery/chemotherapy
21 4 F 67 pT1a pN1 IIA Squamous cell carcinoma Surgery/chemotherapy
22 4 F 64 pT2b pN0 IIA Adenocarcinoma Surgery/chemotherapy
23 4 F 73 pT2a pN1 IIA Small cell carcinoma Surgery/chemotherapy
24 4 M 63 pT1a pN1 IIA Adenocarcinoma Surgery/chemotherapy
25 4 M 75 pT2a pN1 IIA Squamous cell carcinoma Surgery/chemotherapy
26 4 M 64 pT2b pN0 IIA Carcinoid Surgery
27 4 M 68 pT1a pN2 IIIA Adenocarcinoma Surgery
28 4 F 69 pT1b pN2 IIIA Adenocarcinoma Surgery/chemotherapy
29 4 M 63 cT1a cN2 cM0 IIIA Small cell carcinoma Chemotherapy
30 4 F 60 pT3 pN0 IIB Squamous cell carcinoma Surgery/radiotherapy
31 4 M 66 cT4 cN3 cM1b IV Adenocarcinoma Chemotherapy/radiotherapy
32 4 M 64 cT3 cN2 cM1b IV Squamous cell carcinoma Palliative
33 3 (3 months) M 68 pT1a pN0 IA Adenocarcinoma (two primaries) Surgery
34 3 (12 months) M 69 pT1a pN0 IA Adenocarcinoma Surgery
35 3 (12 months) M 61 pT1a pN0 IA Squamous cell carcinoma Surgery
36 3 (12 months) M 70 pT1a pN0 IA Adenocarcinoma Surgery
37 3 (3 months) F 70 pT1aNx† IA Adenocarcinoma Surgery
38 3 (12 months) M 66 pT1b pN0 IA Squamous cell carcinoma Surgery
39 3 (12 months) F 69 cT1a cN0 cM0 IA Adenocarcinoma Radiotherapy
40 3 (12 months) M 71 pT1a pN0 IA Adenocarcinoma Surgery
41 3 (12 months) F 75 cT4 cN2 cM1b IV Adenocarcinoma Surgery (non-pulmonary)
Radiotherapy/chemotherapy
42 2 F 66 pT1a pN0 IA Adenocarcinoma Surgery
*Baseline nodule category—category 4 referred to MDT at baseline, category 3 referred for repeat CT at 3 months and 12 months, category 2 referred for 12 month repeat CT.
†Participant underwent wedge resection. Clinical stage was cT1a cN0 cM0.
MDT, multidisciplinary team.
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with benign disease had surgery (benign resection rate of 10.3%
(4/39)). Details of the UKLS patients with lung cancer with final
pathology, TNM, stage and management are shown in table 3.
Cost effectiveness
A detailed description of the results of the health economics
modelling is given in the online supplementary section. The
baseline estimate for the incremental cost-effectiveness ratio
(ICER) of once-only CT screening relative to symptomatic pres-
entation, under the UKLS protocol, was £8466 per quality
adjusted life year (QALY) (CI £5542 to £12 569).
DISCUSSION
The UKLS pilot has demonstrated that, by using a population-
based approach and a validated risk assessment model, it is
possible to detect lung cancer at an early stage using LDCT
screening. Over 85% of lung cancers detected were stage I or II,
and over 90% of these cases were able to have potentially cura-
tive treatment.
Overall, there was a 1.7% prevalence of lung cancer at base-
line which is higher than that reported by the NLST1 or
NELSON11 12 trials. This reflects the relatively high minimum
risk threshold using the LLPv2 risk model (≥5% over 5 years).
The postal questionnaire approach achieved a 30.7% positive
response rate to the initial mailing, a good response rate for a
clinical trial; however, only 3.5% of the total met the eligibility
criteria. Better targeting of individuals with a high risk will be
needed for a screening programme.13
UKLS has demonstrated that a volumetry-based nodule man-
agement algorithm accurately selected participants for referral
to the MDT, resulting in one of the lowest reported rates of sur-
gical procedures for benign disease (10.3%). The trial has also
confirmed the very low rate of malignancy in small nodules
shown in NELSON.14 Only one (0.2%) participant with
nodules between 15 and 50 mm3 (or 3–5 mm diameter, if
volumetry not possible) was proved to have lung cancer within
a 12-month period. The rate of malignancy was thus well below
the baseline risk in screening populations.
We have defined the terms false positive and interval imaging
rates, thus encapsulating the concept of the level of harm to the
participants. This distinction informs the clinician of the rates
potentially associated with significant harm and the rate asso-
ciated with the need for follow-up imaging, which may be part
of future screening programmes. The UKLS false-positive rate
was 3.6% and the interval imaging rate was 23.2%.
Our interval imaging rate corresponds to the false-positive
rate reported in NLST (23.3%), in which a positive finding on
CTwas any non-calcified nodule at least 4 mm in diameter.1 In
the NELSON trial lung nodules with a volume >500 mm3 or
those with a volume-doubling time <400 days were regarded as
positive tests. Horeweg et al11 15 reported that over three
screening rounds, 458 (6%) of the 7582 participants screened
had a positive result and 200 (2.6%) were diagnosed with lung
cancer; 3.6% of all NELSON participants (273 out of 7582)
had a false-positive screening result. This corresponds to our
definition of false-positive rate. However, at the first round in
NELSON, 19% of cases had indeterminate findings, which
required a repeat scan to assess growth.11
The modelled ICER of once-only CT screening under the
UKLS protocol was of the order of £9000 per QALY. This is
broadly consistent with the ICERs of other recent studies, once
allowance is made for differential efficiency of screening proto-
cols. The ICER would be less favourable if there were substan-
tial overdiagnosis but better if smoking cessation were
improved. The prevalence of lung cancer was consistent with
the risk status of the UKLS recruits, so substantial overdiagnosis
is unlikely.
The comparison of the NLST and UKLS cost-effectiveness
approaches is outlined in table 4. The UKLS ICER is about one-
fifth of the NLST’s costs ($81 000), mainly explained by the
Table 4 Comparison of cost-effectiveness approaches used in the National Lung Cancer Screening Trial (NLST) and UK Lung Cancer Screening
(UKLS)
UKLS NLST16 Consequence (USA compared with the UK)
1 Yield=2.1% of persons screened Yield=2.0% of persons screened Similar yield
2 Single prevalence screen.
Screening and workup costs per
person=£212=$327 at current
exchange rates (7 July 2015)
3 screens to produce similar yield
Screening and workup costs per
person screened=$1965 (table 2)
Far more resources devoted to initial detection in USA
Any US resource has a higher unit cost
3 Net treatment costs per person
(screen-detected vs no screening)=
£60=$92
Net treatment costs per person (screen detected vs no
screening)=$175
US costs treatment costs higher
4 Costs of patient time and travel to
appointments are NOT included in
total costs:
the evaluation adopts an NHS
perspective, as recommended by NICE
Costs of patient time and travel to appointments are included
in total cost:
the evaluation adopts a social perspective, as recommended by
the US Panel on Cost-Effectiveness in Health and Medicine
Inclusion of patient costs makes US screening and
management appear to be more expensive (and less cost
effective)
5 Outcome estimate calculations based
on life table survival estimates
Outcome estimates calculations based on life table survival
estimates
Similar life table survival estimation method used in both
trials
6 Incremental quality adjusted life years
(QALYs) gained per person
screened=0.03
Incremental QALYs gained per person screened=0.02 overall,
but 0.03 in the age range 60–69
Gains per person screened appear essentially similar
7 UKLS modelling based on 1 year
£8466 per QALY gained (CI £5542 to
£12 569)
$13 071 per QALY gained (CI $8556
to $19 405)
NLST
$81 000 per QALY gained (5% CI 52 000 to 186 000).
Calculations based on quintiles 4 and 5, accounts for a
significantly higher proportion of the lung cancer deaths:
costings: 4th quintile $32,000/QALY; 5th quintile $52,000/QALY
(ie, £20,921; £33,996)
Allowing for the fact that the medical care in the USA is
more expensive than the UK, the NLST ICER would be at
least halved, if the screening had been confined to the two
highest risk quintiles
NICE, National Institute for Health and Care Excellence.
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differences in unit costs and in the intensity of resource use to
detect and manage the same proportion of cancers. The UKLS
was a single screen compared with the NLST’s three annual
screens but both gave similar yields of lung cancer.
One of the limitations of our analysis is that the mortality
benefit had to be estimated from NLST. Interestingly, estimates
from both NLST and UKLS were similar, despite the fact that
UKLS targeted a higher risk group (table 4).
The main shortcoming of the UKLS is that it is a pilot study
and is not powered for a long-term mortality comparison in iso-
lation. However, it is planned to pool the UKLS data, including
mortality data, from both arms with the European screening
trials,17 including NELSON, in 2016.
In summary, the UKLS pilot has shown that CT screening in
the UK is possible using a risk prediction model that avoids the
selection of people at very low risk who are unlikely to
benefit,18 and a nodule management algorithm that effectively
manages indeterminate CT findings, yet detects a high number
of early stage lung cancers.
Taking the UKLS pilot trial data in consort with the NLST
mortality data, health economics modelling showed a promising
ICER. However, if CT screening is adopted, efforts to maximise
cost effectiveness should be made, such as integrated smoking
cessation. The results from the NELSON trial and the pooled
UKLS and NELSON trial data will likely influence the decision
to undertake lung cancer screening in the UK.19 20
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